BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update

Reuters08:44

** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024

** Biotech firm announces positive update from IMP761 first-in-human Phase I study, a LAG-3 agonist antibody for autoimmune diseases

** Co reports dose-dependent immunosuppressive effects of IMP761 against a strong foreign antigen, maintaining a favorable safety profile

** Further updates for trial expected in H1 CY2026 - Immutep

** IMM down 12.3% YTD

(Reporting by Keshav Singh Chundawat in Bengaluru)

((Keshav.singhchundawat@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593545170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 08:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593545170","market":"nz","top_or_hot":-1,"title":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update</title></head><body><p>** Shares of Australia's Immutep <span>IMM.AX</span> rise as much as 3.8% to A$0.415, their highest since September 13, 2024</p><p>** Biotech firm <span>announces</span> positive update from IMP761 first-in-human Phase I study, a LAG-3 agonist antibody for autoimmune diseases</p><p>** Co reports dose-dependent immunosuppressive effects of IMP761 against a strong foreign antigen, maintaining a favorable safety profile</p><p>** Further updates for trial expected in H1 CY2026 - Immutep</p><p>** IMM down 12.3% YTD</p><p> (Reporting by Keshav Singh Chundawat in Bengaluru)</p><p> ((Keshav.singhchundawat@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 08:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update</title></head><body><p>** Shares of Australia's Immutep <span>IMM.AX</span> rise as much as 3.8% to A$0.415, their highest since September 13, 2024</p><p>** Biotech firm <span>announces</span> positive update from IMP761 first-in-human Phase I study, a LAG-3 agonist antibody for autoimmune diseases</p><p>** Co reports dose-dependent immunosuppressive effects of IMP761 against a strong foreign antigen, maintaining a favorable safety profile</p><p>** Further updates for trial expected in H1 CY2026 - Immutep</p><p>** IMM down 12.3% YTD</p><p> (Reporting by Keshav Singh Chundawat in Bengaluru)</p><p> ((Keshav.singhchundawat@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMM.AU","symbol_name":"IMMUTEP LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT00R:1","article_id":"2593545170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593545170","pubTimestamp":1766450664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech fir","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMM.AU":"IMMUTEP LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"BUZZ-澳大利亚Immutep因IMP761试验更新积极而创下15个月新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9},"content_text":"BUZZ-Australia's Immutep hits 15-month high on positive IMP761 trial update** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024** Biotech firm announces positive update from IMP761 first-in-human Phase I study, a LAG-3 agonist antibody for autoimmune diseases** Co reports dose-dependent immunosuppressive effects of IMP761 against a strong foreign antigen, maintaining a favorable safety profile** Further updates for trial expected in H1 CY2026 - Immutep** IMM down 12.3% YTD (Reporting by Keshav Singh Chundawat in Bengaluru) ((Keshav.singhchundawat@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593545170","isCrawlerRequest":true}